摘要
勃起性功能障碍通常是血管性障碍所引起的,且经常与男性的心血管疾病相关联。磷酸二酯酶-5抑制剂的引入已经彻底改变了勃起功能障碍患者的治疗。目前,有效的磷酸二酯酶-5抑制剂具有独特的药效动力学和药效学性能,从而可以根据患者的特点和需求进行定制性治疗。磷酸二酯酶-5抑制剂具有血管舒张性质且发挥全身的血流动力作用,这点在与其他的心血管药物共同给药时需要被考虑到。特别需要注意α-阻滞剂,当它与硝酸盐共同使用时,这是显然不当的,这是因为它们一起合用将有威胁生命的低血压的风险。本文介绍了性治疗的出现,描述了市场上可买到的磷酸二酯酶-5抑制剂的作用机制和具体特征,概述了这些药物的功效和安全性,特别强调了其在心血管系统方面的功效和安全性,且讨论了每种药物用于个体患者的临床标准。
关键词: 心血管危险,勃起功能障碍,女性性功能障碍,磷酸二酯酶-5抑制剂,西地那非,他达拉非,伐地那非
Current Drug Targets
Title:PDE-5 Inhibitors: Clinical Points
Volume: 16 Issue: 5
Author(s): Michael Doumas, Antonios Lazaridis, Niki Katsiki and Vasilios Athyros
Affiliation:
关键词: 心血管危险,勃起功能障碍,女性性功能障碍,磷酸二酯酶-5抑制剂,西地那非,他达拉非,伐地那非
摘要: Erectile dysfunction is usually of vascular origin and is frequently encountered in men with cardiovascular disease. The introduction of phosphodiesterase-5 inhibitors has revolutionized the management of patients with erectile dysfunction. Currently available phosphodiesterase-5 inhibitors have distinct pharmacokinetic and pharmacodynamic properties, thus permitting for tailoring sexual therapy according to patient characteristics and needs. Phosphodiesterase-5 inhibitors possess vasorelaxing properties and exert systemic hemodynamic effects, which need to be taken into account when other cardiovascular drugs are co-administered. Special caution is needed with alpha-blockers, while the co-administration with nitrates is contra-indicated due to the risk of life-threatening hypotension. This review presents the advent of sexual therapy, describes the mechanism of action and the specific characteristics of commercially available phosphodiesterase-5 inhibitors, summarizes the efficacy and safety of these drugs with special emphasis on the cardiovascular system, and discusses the clinical criteria used for the selection of each drug for the individual patient.
Export Options
About this article
Cite this article as:
Michael Doumas, Antonios Lazaridis, Niki Katsiki and Vasilios Athyros , PDE-5 Inhibitors: Clinical Points, Current Drug Targets 2015; 16 (5) . https://dx.doi.org/10.2174/1389450115666141111111301
DOI https://dx.doi.org/10.2174/1389450115666141111111301 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design Reversible Michael Additions: Covalent Inhibitors and Prodrugs
Mini-Reviews in Medicinal Chemistry Effect of Depression on Self-Management Behaviors and Health Outcomes in Adults with Type 2 Diabetes
Current Diabetes Reviews Synthesis and Applications of Bisheterocyclic Compounds
Current Organic Synthesis Potential Strategies for Minimizing Mechanism-Based Inhibition of Cytochrome P450 3A4
Current Pharmaceutical Design New Developments in the Diagnosis and Management of Resistant Hypertension
Current Medicinal Chemistry The History and Rationale for Monoclonal Antibodies in the Treatment of Hematologic Malignancy
Current Pharmaceutical Biotechnology Mechanisms of Fetal and Neonatal Renal Impairment by Pharmacologic Inhibition of Angiotensin
Current Medicinal Chemistry Non-Invasive Methods and Techniques for Central Blood Pressure Estimation: Procedures, Validation, Reproducibility and Limitations
Current Pharmaceutical Design Recent Advances in the Understanding of Sepsis-Induced Alterations in the Neuroendocrine System
Endocrine, Metabolic & Immune Disorders - Drug Targets Expression of Mastoparan B, a Venom Peptide, Via Escherichia coli C43 (DE3) Coupled with an Artificial Oil Body-Cyanogen Bromide Technology Platform
Protein & Peptide Letters Ethanol Metabolism and Effects: Nitric Oxide and its Interaction
Current Clinical Pharmacology Preeclampsia Prediction in Type 1 Diabetes and Diurnal Blood Pressure Methodology
Current Hypertension Reviews The Potential of Tetrandrine Against Gliomas
Anti-Cancer Agents in Medicinal Chemistry Antibodies Against Recombinant Catalytic Domain of Lethal Toxin of Clostridium sordellii Neutralize Lethal Toxin Toxicity in HeLa Cells
Protein & Peptide Letters Aortic Stenosis, Aortic Regurgitation and Arterial Hypertension
Current Vascular Pharmacology Melatonin Receptor Agonist Agomelatine: A New Drug for Treating Unipolar Depression
Current Pharmaceutical Design Therapy in Prion Diseases
Current Topics in Medicinal Chemistry "Take and Run" and "Take and Hold" Therapeutical Electromagnetic Field Application Modalities in Physiotherapy: Some Clinically Significant Pathways of Action
Current Chemical Biology New Mucoadhesive Polymeric Film for Ophthalmic Administration of Acetazolamide
Recent Patents on Drug Delivery & Formulation